- Deanne Taylor advocates for children’s health research, pushing for pediatric-focused studies in the Human Cell Atlas to address gene expression differences. - A $38.5M NIH grant funds dGTEx, creating a pediatric gene expression database to study healthy tissue development. - The dGTEx project aims to improve drug safety and disease understanding by mapping gene activity in children’s organs. - Taylor unites researchers to build a holistic view of pediatric development, bridging gaps in medical research for children.

- Open-source AI framework OneGenome aims to decode rare diseases and promote equitable precision medicine access. - Patients face years of inconclusive tests, with disease causes hidden in complex DNA sequences. - OneGenome uses genomic data and medical logic to interpret gene mutations' clinical impact. - Developed by integrating Genos (trained on global genomes) with large language models.

Here are four clear bullet points summarizing the article: • Base44, a vibe-coding platform acquired by Wix for $80 million last year, is rolling out its own AI model to support users in creating apps with natural language. • The move allows Base44 to optimize latency, cost, and efficiency, potentially staying ahead of competitors like Lovable, which relies on external models. • The company's decision to develop its own LLM stems from multiple factors, including cost reduction and improved margins, which would benefit its parent company despite recent layoffs. • Base44 is positioning itself as a vertically integrated vibe-coding application, owning its distribution, data, and infrastructure, which could be a key differentiator in the market.

Here are four clear bullet points summarizing the article: • Insilico Medicine and Human Longevity partner to advance personalized health research using AI algorithms and genomic data. • The partnership values the global longevity market at $5.3 trillion, projected to reach $8 trillion by 2030, driven by an aging population and rising consumption demand. • Insilico's CEO describes the collaboration as a "conceptually new type of personal longevity AI" that will help discover new drugs for everyone, not just individuals. • The partnership is a multimillion-dollar co-development collaboration, with no disclosed investment amount, but shares of Insilico Medicine declined 4.21% to HK$48.28 apiece on Tuesday and further to HK$48.10 on Wednesday.

Here are four clear bullet points summarizing the article: • Curium Life Technologies aims to address the gap between surgical procedures and learning from them by turning intraoperative data into real-time insights for surgeons. • The company's first product, SurgiMeasure, focuses on real-time intraoperative measurements during procedures like bariatric surgery and hernia repair, providing support for clinical judgment rather than replacing it. • Curium has built a team with both clinical and technical expertise, working with over 50 expert surgeon collaborators across India, the US, and other regions to develop its products and secure letters of intent for structured data acquisition. • The company plans to raise additional funding to scale operations, expand clinical data, and enter global markets, with a long-term goal of building an AI layer for surgery that supports decisions across procedures and specialities.

Here are four clear bullet points summarizing the article: • ByteDance's AI Drug Discovery unit (Anew Therapeutics) has teams in Boston, Rio de Janeiro, and Barcelona, with 36 core members and a scientific advisory board. • The team presented one pipeline drug candidate at Immunology2026 in Boston, designed by generative AI for autoimmune diseases, and showcased its framework and therapies powered by AI. • Anew Labs' head of data attended the International Conference on Learning Representations in Rio de Janeiro to advance deep learning, while the head of computational chemistry went to the 2026 Free Energy Workshop in Barcelona. • The unit's official website lists notable scientists, including former presidents and principal scientists from biotech companies Innovent Biologics, Amgen, and Takeda California.